LeMaitre Vascular, Inc. (LMAT) Scheduled to Post Earnings on Tuesday
LeMaitre Vascular, Inc. (NASDAQ:LMAT) is scheduled to release its earnings data after the market closes on Tuesday, October 24th. Analysts expect LeMaitre Vascular to post earnings of $0.20 per share for the quarter. LeMaitre Vascular has set its Q3 guidance at $0.20 EPS and its FY17 guidance at $0.79 EPS.
LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.17 by $0.06. The company had revenue of $25.80 million during the quarter, compared to analysts’ expectations of $25.42 million. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. LeMaitre Vascular’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.14 earnings per share. On average, analysts expect LeMaitre Vascular to post $0.79 EPS for the current fiscal year and $0.86 EPS for the next fiscal year.
Shares of LeMaitre Vascular, Inc. (NASDAQ LMAT) opened at 37.08 on Tuesday. The stock has a 50 day moving average of $37.56 and a 200-day moving average of $31.81. LeMaitre Vascular, Inc. has a 12 month low of $18.55 and a 12 month high of $39.29. The company has a market cap of $705.34 million, a PE ratio of 52.97 and a beta of 0.67.
LeMaitre Vascular declared that its Board of Directors has approved a stock repurchase program on Thursday, July 27th that authorizes the company to repurchase $7.50 million in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 1.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.
ILLEGAL ACTIVITY WARNING: “LeMaitre Vascular, Inc. (LMAT) Scheduled to Post Earnings on Tuesday” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/17/lemaitre-vascular-inc-lmat-scheduled-to-post-earnings-on-tuesday.html.
In other news, insider David B. Roberts sold 48,317 shares of LeMaitre Vascular stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $33.12, for a total transaction of $1,600,259.04. Following the completion of the sale, the insider now owns 30,105 shares in the company, valued at approximately $997,077.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Peter R. Gebauer sold 22,067 shares of LeMaitre Vascular stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $34.28, for a total value of $756,456.76. Following the sale, the insider now owns 4,486 shares of the company’s stock, valued at approximately $153,780.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 373,121 shares of company stock valued at $12,825,992. Corporate insiders own 23.70% of the company’s stock.
Several research analysts have commented on the company. Canaccord Genuity restated a “hold” rating and issued a $30.00 target price on shares of LeMaitre Vascular in a research note on Monday, October 9th. Zacks Investment Research downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, September 28th. Stifel Nicolaus restated a “buy” rating and issued a $32.00 target price (up previously from $29.00) on shares of LeMaitre Vascular in a research note on Sunday, July 30th. BidaskClub downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Finally, Benchmark Co. upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, July 28th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $32.00.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.